Founded in July 2017, Acurx Pharmaceuticals, LLC is an early stage biopharmaceutical company focused on developing
antibiotics that address difficult to treat bacterial infections. Acurx’s initial antibiotic product development candidate is
ACX-362E, a DNA polymerase inhibitor with a novel mechanism of action for oral treatment of Clostridium difficile
Infections, or “CDI.” Acurx acquired the worldwide rights to ACX-362E (also known as “GLS-362E”) from GLSynthesis
Inc. in February, 2018. Acurx is currently reviewing other early stage antibiotic development candidates for potential
development/acquisition that address difficult to treat bacterial infections.